Literature DB >> 33521010

Comparison of Liver Biomarkers in 288 COVID-19 Patients: A Mono-Centric Study in the Early Phase of Pandemic.

Haozhi Fan1, Jinyuan Cai2, Anran Tian2, Yuwen Li3, Hui Yuan2, Zhengyi Jiang4, Yunxi Yu5, Lili Ruan6, Pingping Hu2, Ming Yue2, Nian Chen2, Jun Li2, Chuanlong Zhu2,7.   

Abstract

Background and Aims: Recent reports have indicated that hepatic dysfunction occurred in a proportion of patients with coronavirus disease 2019 (COVID-19). We aimed to compare and describe the liver biomarkers in different subtypes of COVID-19 patients.
Methods: This study enrolled 288 COVID-19 patients in Huangshi Hospital of Traditional Chinese Medicine. All patients were divided into ordinary, severe, and critical groups according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Demographic, clinical characteristics and liver biomarkers were compared among the three groups.
Results: During hospitalization, AST, TBiL, and ALP levels in ordinary and severe patients fluctuated within the normal range with a rising trend in critical patients except AST. ALT and GGT levels fluctuated within the normal range showing an upward trend, while LDH levels in the critical group exceeded the normal range. Prealbumin showed an upward trend, especially in the severe group. At discharge, AST and LDH levels in ordinary and severe groups were lower than their baselines but increased in the critical group. In contrast to albumin, TBiL levels were increased in ordinary and critical groups while decreased in the severe group. The stratified analysis revealed factors affecting liver function in critical cases included highest temperature ≥38.0°C, age ≥60 and symptom of hypoxemia. Conclusions: COVID-19 can cause severe hepatic dysfunction in critical patients, requiring early monitoring and intervention. LDH, ALP, GGT, TBiL, prealbumin, and albumin may be helpful for evaluating and predicting disease prognosis due to their correlation with disease severity in COVID-19.
Copyright © 2021 Fan, Cai, Tian, Li, Yuan, Jiang, Yu, Ruan, Hu, Yue, Chen, Li and Zhu.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; hepatic dysfunction; liver biomarkers; liver injury

Year:  2021        PMID: 33521010      PMCID: PMC7843802          DOI: 10.3389/fmed.2020.584888

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  4 in total

Review 1.  Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity.

Authors:  Tarun Sahu; Babita Pande; Manasa Pl; Henu Kumar Verma
Journal:  World J Hepatol       Date:  2022-06-27

Review 2.  The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy.

Authors:  Guyi Wang; Bing Xiao; Jiayi Deng; Linmei Gong; Yi Li; Jinxiu Li; Yanjun Zhong
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

3.  Diabetes Mellitus May Exacerbate Liver Injury in Patients with COVID-19: A Single-Center, Observational, Retrospective Study.

Authors:  Mutsuko Minata; Kouji H Harada; Tomoyuki Yamaguchi; Tomoko Fujitani; Hidemitsu Nakagawa
Journal:  Diabetes Ther       Date:  2022-09-22       Impact factor: 3.595

4.  Effects of lymphocyte, C-reactive protein and prealbumin levels on clinical typing and course of disease in children infected with novel coronavirus.

Authors:  Jing Bi; Yuanda Zhang; Jingzhi Zhang; Qian Han; Chaoyu Ji; Weina Zhen
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.